MRNA Earnings Prediction
The chart below shows how MRNA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MRNA sees a +2.80% change in stock price 10 days leading up to the earnings, and a -0.27% change 10 days following the report. On the earnings day itself, the stock moves by +1.13%. This data can give you a slight idea of what to expect for the next quarter's release.
MRNA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.86B
1.69%
672.61%
Gross Margin
83.89%
474.68%
44.41%
Operating Margin
7.73%
107.03%
-101.38%
Net Margin
0.70%
100.35%
-100.13%
EPS
0.03
100.31%
-100.90%
No Data Available
MRNA Earnings Analysis
Moderna, Inc. Common Stock Corporation (MRNA.O) Earnings Conference Call
Positive
Significant Revenue Increase: 1. Strong Revenue Growth: Moderna reported $1.9 billion in revenue for Q3 2024, marking a significant increase compared to the previous year.
Net Income Recovery: 2. Improved Net Income: The company achieved a net income of $13 million in Q3 2024, a notable recovery from a net loss of $3.6 billion in Q3 2023.
Cost Management Success: 3. Significant Cost Reductions: Operating expenses were reduced by $500 million year-over-year, demonstrating effective cost management across various departments.
Market Share Expansion: 4. Increased Market Share: Moderna captured a 40% share of retail COVID vaccine doses in the U.S. for the current season, reflecting strong competitive positioning.
Strong Cash Reserves: 5. Robust Cash Position: The company ended the quarter with $9.2 billion in cash and investments, providing a solid financial foundation for future growth.
Negative
Declining mRESVIA Sales: 1. Declining RSV Sales: Moderna's mRESVIA sales were only $10 million in Q3 2024, significantly below expectations due to missing most of the contracting season and facing substantial inventory from competitors.
Decline in International Sales: 2. Lower International Sales: International sales of $0.6 billion in Q3 2024 were lower compared to the same period in 2023, which had benefited from deferred orders from 2022.
Cash Position Decline: 3. Reduced Cash Position: Cash and investments decreased to $9.2 billion at the end of Q3 2024, down from $10.8 billion at the end of Q2 2024, primarily due to ongoing R&D expenses and operating activities.
Q4 2024 Sales Forecast: 4. Product Sales Guidance: The company expects Q4 2024 product sales to be between $0.8 billion and $1.3 billion, which implies a significant decline compared to previous quarters, driven by flat to down vaccination rates.
Tax Expense Reduction: 5. Tax Expense Impact: The income tax for Q3 2024 was $8 million, a significant reduction from $1.7 billion in the same period last year, largely due to a valuation allowance on deferred tax assets established in Q3 2023.
MRNA FAQs
How does MRNA typically perform around its earnings report dates?
Is Moderna (MRNA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MRNA Earning Call Sentiment
Moderna (MRNA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
MRNA.O
-3.33%Positive
The earnings call summary presents a mixed picture: strong EPS improvement and significant cost reductions are positive, but lower international sales and RSV vaccine sales below expectations are negatives. The Q&A session reveals management's cautious tone, especially around future revenue guarantees and market dynamics, which could temper investor enthusiasm. The reduced sales guidance and lack of clear guidance on market share and product transitions further contribute to a neutral sentiment, balancing the positive financial improvements with uncertainties in future growth and market positioning.
